4DMedical Ltd ( (AU:4DX) ) has provided an update.
4DMedical Limited announced an upcoming investor webinar and Q&A session to discuss its 1H FY2025 Half Year Results. The session, led by CEO Dr. Andreas Fouras, aims to update shareholders and investors on the company’s performance and strategic direction. This event underscores 4DMedical’s commitment to transparency and engagement with its stakeholders, potentially impacting its market positioning and investor relations.
More about 4DMedical Ltd
4DMedical Limited is a global leader in medical technology, specializing in respiratory imaging technology. The company leverages advanced imaging and AI-powered solutions to provide detailed insights into lung function, facilitating earlier and more accurate diagnoses of respiratory diseases. Central to its offerings is the patented XV Technology®, which dynamically measures ventilation throughout the lungs. 4DMedical’s solutions, including the FDA-cleared XV Lung Ventilation Analysis Software, integrate with existing hospital systems via a SaaS model. The company’s recent acquisition of Imbio enhances its capabilities in AI-driven diagnostics for lung and cardiothoracic diseases.
YTD Price Performance: -12.50%
Average Trading Volume: 939,388
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$173.9M
See more insights into 4DX stock on TipRanks’ Stock Analysis page.